company background image
AMRX logo

Amneal Pharmaceuticals NasdaqGS:AMRX Stock Report

Last Price

US$7.45

Market Cap

US$2.2b

7D

0.9%

1Y

127.1%

Updated

22 Jul, 2024

Data

Company Financials +

Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX Stock Report

Market Cap: US$2.2b

AMRX Stock Overview

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

AMRX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Amneal Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amneal Pharmaceuticals
Historical stock prices
Current Share PriceUS$7.45
52 Week HighUS$7.74
52 Week LowUS$2.99
Beta1.23
11 Month Change12.03%
3 Month Change37.96%
1 Year Change127.13%
33 Year Change54.24%
5 Year Change104.11%
Change since IPO-50.37%

Recent News & Updates

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Recent updates

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Dec 10

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Nov 28
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Sep 24

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Aug 08
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Amneal Pharmaceuticals Could Have An Upbeat Q2

Jul 10

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20
Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Aug 04

Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of Debt

Apr 16
Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of Debt

Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old Management

Mar 30

Shareholder Returns

AMRXUS PharmaceuticalsUS Market
7D0.9%-2.9%-1.1%
1Y127.1%17.2%20.0%

Return vs Industry: AMRX exceeded the US Pharmaceuticals industry which returned 17% over the past year.

Return vs Market: AMRX exceeded the US Market which returned 19% over the past year.

Price Volatility

Is AMRX's price volatile compared to industry and market?
AMRX volatility
AMRX Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: AMRX's share price has been volatile over the past 3 months.

Volatility Over Time: AMRX's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20027,850Chirag Patelamneal.com

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Amneal Pharmaceuticals, Inc. Fundamentals Summary

How do Amneal Pharmaceuticals's earnings and revenue compare to its market cap?
AMRX fundamental statistics
Market capUS$2.23b
Earnings (TTM)-US$168.69m
Revenue (TTM)US$2.50b

0.9x

P/S Ratio

-13.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMRX income statement (TTM)
RevenueUS$2.50b
Cost of RevenueUS$1.58b
Gross ProfitUS$913.40m
Other ExpensesUS$1.08b
Earnings-US$168.69m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 09, 2024

Earnings per share (EPS)-0.55
Gross Margin36.61%
Net Profit Margin-6.76%
Debt/Equity Ratio-15,850.3%

How did AMRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.